Vaxcyte (PCVX) Current Deferred Revenue (2019 - 2020)
Vaxcyte's (PCVX) quarterly Current Deferred Revenue came in at $14000.0 in Q4 2020, down 26.32% year-on-year from $19000.0 in Q1 2020, and down 48.15% on a QoQ basis from $27000.0 in Q3 2020.
Vaxcyte (PCVX) Current Deferred Revenue (2019 - 2020) Analysis & Trends
Vaxcyte (PCVX) has 2 years of Current Deferred Revenue data on file, last reported at $14000.0 in Q4 2020.
- On a quarterly basis, Current Deferred Revenue fell 26.32% year-over-year to $14000.0 in Q4 2020; TTM through Dec 2020 was $14000.0, a 26.32% decrease from a year earlier, with the FY2020 full-year figure at $14000.0, down 26.32% from the prior year.
- Current Deferred Revenue for Q4 2020 stood at $14000.0, down from $27000.0 in the prior quarter.
- Over the last five years, Current Deferred Revenue for PCVX reached as high as $27000.0 in Q3 2020 and fell as low as $14000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Vaxcyte | 7.76 Bn | 7.76 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 14,000.00 |
| Sep 30, 2020 | 27,000.00 |
| Jun 30, 2020 | 25,000.00 |
| Dec 31, 2019 | 19,000.00 |